Company Overview and News
A MORE optimistic outlook for Spain's growth is predicted for this and next year by the International Monetary Fund (FMI) now that it considers the Catalunya political crisis to be over, in terms of its possible effects on the economy.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
The French economy grew slower than estimated, per the Bank of France, primarily owing to a slowdown in manufacturing activity. The bank’s lower growth estimate for the first quarter is indicative of a somewhat broader slowdown in the Euro zone. European Central Bank (ECB) Executive Board member Benoit Coeure thinks the Euro bloc is witnessing a correction rather than a slowdown, per a Reuters article.
It’s easy to overlook small monthly expenses such as a Netflix, Inc. (NASDAQ:NFLX) or Spotify Technology SA (NYSE:SPOT) subscription. But even those small dollar amounts can add up. With the rise of discount and even free brokerages, it’s ever-easier to put small amounts of capital to work without paying exorbitant fees and buy cheap stocks.
The news that Deutsche Bank AG (USA) (NYSE:DB) has fired current CEO John Cryan, replacing him with Co-deputy chief executive Christian Sewing, appears to have stemmed the bleeding in DB stock.
DEPARTMENT store chain El Corte Inglés is calling for a European online shopping platform to be set up in order to competewith US giant Amazon and China's Alibaba, involving several major retailers working together.
The Eurozone was a strong performer in 2017, courtesy of strong economic growth and fundamentals. However, the global market selloff and trade war fears weighed on the performance of the 19-nation bloc in the first quarter of 2018 (read: ETFs to be Impacted by Trump's Tariff Exemptions).
BARCELONA is set to launch its own currency next month – the REC, which residents can spend in 10 neighbourhoods at first and which may spread to more areas of the metropolitan zone.
David Chapman says interest in crypto is rising from institutions, including private banks, many of whom acting on demand from their clients
Barclays PLC’s (BCS - Free Report) long-term issuer and senior unsecured debt ratings have been downgraded from Baa2 to Baa3 by Moody's Investors Service. The rating agency also assigned a notional Baseline Credit Assessment (BCA) of baa3 to the company for the first time. The outlook is stable. Alongside, the long-term deposit and senior unsecured debt ratings of Barclays Bank PLC have been downgraded from A1 to A2.
MAINS gas tariffs will drop from today (Easter Sunday) thanks to a reduction in the price of raw material in international markets.
ELECTRICITY in Spain became the cheapest in the European Union on Thursday and has remained so ever since – the second time this has happened in a fortnight.
I explain here what CoCos are, basically why they exist, and why they are based on fakery.
The good news here is that this macroeconomic slowdown is temporary, while the sector’s fundamentals remain intact.
Banco de Sabadell is a Spanish bank with a strong position in Corporate and SMEs in its domestic market, and also has good growth prospects internationally.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...